A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
Study Details
Study Description
Brief Summary
The main aim of this study is to determine safety and tolerability of modakafusp alfa given together with daratumumab to find out the best treatment dose. Another aim of this study is to learn more about the characteristics of modakafusp alfa.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
The drug being tested in this study is called modakafusp alfa (TAK-573). Modakafusp alfa is being tested to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy in combination with daratumumab in participants with relapsed or refractory multiple myeloma (RRMM). The study will consist of 2 phases: Phase 1 Dose Escalation and a Phase 2a Dose Finding.
The study will enroll approximately 58 patients. Approximately 18 participants will be enrolled in the Phase 1 Dose Escalation/De-escalation and two dose levels of modakafusp alfa in combination with daratumumab SC will be selected to be further explored in the randomized Phase 2a Dose Finding part of the study wherein, approximately 40 participants will be randomly assigned by chance (like flipping a coin) to one of the two treatment groups:
-
Phase 2a Dose Finding: Modakafusp Alfa (DL1) + Daratumumab
-
Phase 2a Dose Finding: Modakafusp Alfa (DL2) + Daratumumab This multi-center trial will be conducted worldwide. The overall time to participate in this study is approximately 60 months. Participants who discontinue study drug treatment for reasons other than progressive disease will continue progression-free survival (PFS) follow-up every 4 weeks from the end of treatment (EOT) visit until the occurrence of progressive disease, death, the start of subsequent systemic antineoplastic therapy, study termination, whichever occurs first.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Phase 1 Dose Escalation Modakafusp alfa 60 to 240 mg, infusion, intravenously, once every 4 weeks (Q4W) with daratumumab 1800 mg, subcutaneously (SC), once weekly (QW) in Cycles 1 and 2, twice weekly (Q2W) in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression. |
Drug: Modakafusp Alfa
Modakafusp alfa intravenous infusion
Other Names:
Drug: Daratumumab
Daratumumab SC injection
|
| Experimental: Phase 2a Dose Finding: Modakafusp Alfa (DL1) + Daratumumab Modakafusp alfa at dose level 1 (DL1) [selected from Phase 1 Dose Escalation] with daratumumab SC 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression. |
Drug: Modakafusp Alfa
Modakafusp alfa intravenous infusion
Other Names:
Drug: Daratumumab
Daratumumab SC injection
|
| Experimental: Phase 2a Dose Finding: Modakafusp Alfa (DL2) + Daratumumab Modakafusp alfa at dose level 2 (DL2) [selected from Phase 1 Dose Escalation] with daratumumab SC 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression. |
Drug: Modakafusp Alfa
Modakafusp alfa intravenous infusion
Other Names:
Drug: Daratumumab
Daratumumab SC injection
|
Outcome Measures
Primary Outcome Measures
- Phase 1: Number of Participants with Dose Limiting Toxicities (DLT) [Cycle 1 (cycle length=28 days)]
DLT will be defined as any of the TEAEs that occur during Cycle 1 and are considered by the investigator to be at least possibly related to modakafusp alfa. Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.
- Phase 1: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Per Severity [Up to 60 months]
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Severity grades for TEAEs will be evaluated as per the NCI CTCAE Version 5.0.
- Phase 2a: Overall Response Rate (ORR) [Up to 60 months]
ORR is defined as the percentage of participants who achieve a confirmed partial response (PR) or better during the study in the safety population. ORR will be assessed by the investigator per International Myeloma Working Group (IMWG) criteria.
Secondary Outcome Measures
- Phase 1: Cmax: Single-Dose Maximum Observed Serum Concentration for Modakafusp Alfa [Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
- Phase 1: Tmax: Time to First Occurrence of Maximum Serum Concentration (Cmax) for Modakafusp Alfa [Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
- Phase 1: AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Modakafusp Alfa [Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
- Phase 1: AUClast: Area Under the Serum Concentration-time Curve from Time 0 to Time of the Last Quantifiable Concentration [Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
- Phase 1: Apparent Serum Terminal Disposition Rate Constant for Modakafusp Alfa [Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
- Phase 1: Apparent Serum Terminal Disposition Phase Half-life for Modakafusp Alfa [Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
- Phase 1: Total Clearance After Intravenous Administration for Modakafusp Alfa [Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
- Phase 1: Volume of Distribution at Steady State After Intravenous Administration for Modakafusp Alfa [Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
- Phase 1: Cmax: Single-Dose Maximum Observed Serum Concentration for Daratumumab [Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
- Phase 1: Tmax: Time to First Occurrence of Maximum Serum Concentration (Cmax) for Daratumumab [Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
- Phase 1: Ctrough: Single-Dose and Multiple-dose Observed Concentration at the End of a Dosing Interval for Daratumumab [Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
- Phase 1: AUC∞: Area Under the Serum Concentration-time Curve from Time 0 to Infinity for Daratumumab [Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
- Phase 1: AUClast: Area Under the Serum Concentration-time Curve from Time 0 to Time of the Last Quantifiable Concentration for Daratumumab [Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
- Phase 1: Overall Response Rate (ORR) [Up to 60 months]
ORR is defined as the percentage of participants who achieved a confirmed PR or better during the study in the safety population. ORR will be assessed by the investigator per IMWG criteria.
- Phase 1 and Phase 2a: Duration of Response (DOR) [Up to 60 months]
DOR is defined as the time from the date of first documentation of a confirmed PR or better to the date of first documentation of confirmed progressive disease or death due to any cause, whichever occurs first. DOR will be calculated for confirmed responders only (PR or better). DOR will be assessed by the investigator as per IMWG criteria.
- Phase 1 and Phase 2a: Progression Free Survival (PFS) [up to 60 months]
PFS is defined as the time from the date of the first dose administration of any study drug to the first documentation of confirmed progressive disease or death due to any cause, whichever occurs first. PFS will be assessed by the investigator as per IMWG criteria.
- Phase 1 and Phase 2a: Overall Survival (OS) [Up to 60 months]
OS is defined as the time from the date of the first dose administration of any study drug to the documentation of death due to any cause. OS will be assessed by the investigator as per IMWG criteria.
- Phase 1 and Phase 2a: Number of Participants With Anti-drug Antibodies [Up to 60 months]
- Phase 1 and Phase 2a: Titer of Anti-drug Antibodies [Up to 60 months]
- Phase 1 and Phase 2a: Number of Participants With Neutralizing Antibodies (NAb) Against Study Drug [Up to 60 months]
- Phase 1 and Phase 2a: Rate of Measurable [Minimal] Residual Disease Negative (MRD[-]) Complete Response (CR) [Up to 60 months]
MRD[-] CR rate is defined as the percentage of participants who achieve confirmed CR assessed by the investigator and MRD[-] status using a threshold of 10^-5. The analysis will be based on the response-evaluable population.
- Phase 1 and Phase 2a: Duration of Measurable [Minimal] Residual Disease (MRD) Negativity [Up to 60 months]
Duration of MRD negativity for participants achieving MRD negativity is defined as the time from the date of first documentation of MRD negativity to the first documentation of MRD positivity or confirmed progressive disease, whichever occurs first. It will be calculated for participants achieving MRD negativity only.
- Phase 2a: Clinical Benefit Rate (CBR) [Up to 60 months]
CBR is defined as the percentage of participants who had a confirmed response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), or minimal response based on investigators' disease assessment per IMWG criteria.
- Phase 2a: Duration of Clinical Benefit (DCB) [Up to 60 months]
DCB is defined as the time from the date of first documentation of a minimal response or better to the date of first documentation of confirmed progressive disease or death due to any cause, whichever occurs first. DCB will be calculated for only participants who achieved a minimal response or better. DCB will be assessed by the investigator as per IMWG criteria.
- Phase 2a: Disease Control Rate (DCR) [Up to 60 months]
DCR is defined as the percentage of participants with a confirmed response of sCR, CR, VGPR, PR, minimal response, or stable disease (SD) based on investigators' disease assessment per IMWG criteria.
- Phase 2a: Duration of Disease Control [Up to 60 months]
Duration of disease control is defined as the time from date of first documentation of SD or better to the date of first documentation of confirmed progressive disease or death due to any cause. Duration of disease control will be calculated for only patients who achieved SD or better. It will be assessed by the investigator per IMWG criteria.
- Phase 2a: Time to Progression (TTP) [Up to 60 months]
TTP is defined as the time from the date of randomization to the first documentation of confirmed progressive disease as defined by IMWG criteria, assessed by the investigator. Participants without documentation of confirmed progression will be censored at the date of last adequate disease assessment. The analysis will be based on the intent-to-treat (ITT) population.
- Phase 2a: Time to Response (TTR) [Up to 60 months]
TTR is defined as time from the date of first dose administration of any study drug to the date of the first documentation of a confirmed PR or better. TTR will be calculated for responders only. TTR will be assessed by the investigator per IMWG criteria.
- Phase 2a: Time to Next Treatment (TTNT) [Up to 60 months]
TTNT is defined as the time from the date of first dose administration of any study drug to the date of the first dose initiation of the next line of anticancer therapy for any reason or death from any cause, whichever comes first. Participants who have not started the next-line therapy will be censored at the date last known to be alive before subsequent anticancer therapy.
- Phase 2a: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Per Severity [Up to 60 months]
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Severity grades for TEAEs will be evaluated as per the NCI CTCAE Version 5.0.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Documented multiple myeloma (MM) diagnosis per IMWG criteria.
-
Measurable disease, defined as at least 1 of the following:
-
Serum M protein ≥0.5 grams per deciliter [g/dL] (≥5 g/L) on serum protein electrophoresis (SPEP).
-
Urine M protein ≥200 mg/24 hours on urine protein electrophoresis (UPEP).
-
Serum free light chain (FLC) assay with involved FLC level ≥10 mg/dL (≥100 mg/L) provided serum FLC ratio is abnormal.
-
For participants in the Phase 1 Dose Escalation only:
Must have received at least 3 prior lines of therapy, including at least 1 proteosome inhibitor (PI), 1 immunomodulatory imide drug (IMiD), and 1 anti-CD38 monoclonal antibody (mAb) drug; or who are triple refractory to a PI, an IMiD, and an anti-CD38 mAb drug, regardless of the number of prior line(s) or therapy.
-
For participants in Phase 2a Dose Finding only:
-
Received 1 to 3 prior line(s) of antimyeloma therapy.
-
Must be refractory to prior lenalidomide treatment.
-
Participants must be sensitive (nonrefractory) or naïve to prior anti-CD38 mAb treatment.
-
Documented progressive disease on or after the last regimen.
-
Participants must have PR or better to at least 1 line of prior therapy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at screening.
Exclusion Criteria:
-
Prior exposure to modakafusp alfa.
-
Participant has polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, solitary plasmacytoma, amyloidosis, Waldenström macroglobulinemia, plasma cell leukemia, or lymphoplasmacytic lymphoma.
-
Participant has not recovered from adverse reactions to prior myeloma treatment or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE, Version 5 Grade ≤1 or baseline, except for alopecia.
-
Previous allogeneic stem cell transplant at any time or autologous stem cell transplant (ASCT) within 12 weeks of planned start of dosing.
-
Seropositive for hepatitis B, or known history of seropositivity for hepatitis C or of seropositivity for human immunodeficiency virus (HIV).
-
Participant has congestive heart failure (New York Heart Association Grade ≥II), cardiac myopathy, active ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant arrhythmia requiring therapy including anticoagulants, or clinically significant uncontrolled hypertension.
-
Participant has QT interval corrected by the Fridericia method >480 milliseconds [msec] (Grade ≥2).
-
Participant has a chronic condition that will require the chronic use of systemic corticosteroids >10 milligrams per day (mg/d) of prednisone or equivalent on top of any required corticosteroids for multiple myeloma (MM).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Banner MD Anderson Cancer Center | Gilbert | Arizona | United States | 85234 |
| 2 | Cedars-Sinai Medical Center | Los Angeles | California | United States | 77598 |
| 3 | James R Berenson, MD Inc. | West Hollywood | California | United States | 90069 |
| 4 | Fort Wayne Medical Oncology and Hematology, Inc | Fort Wayne | Indiana | United States | 46060 |
| 5 | HCA Midwest Health (Midwest Ventures Group HCA MidAmerica Division) | Overland Park | Kansas | United States | 66211 |
| 6 | Tulane University Health Sciences Center | New Orleans | Louisiana | United States | 70112 |
| 7 | Floating Hospital for Children at Tufts Medical Center | Boston | Massachusetts | United States | 02111 |
| 8 | Washington University School of Medicine | Saint Louis | Missouri | United States | 63130 |
| 9 | University of Nebraska Medical Center | Omaha | Nebraska | United States | 68198 |
| 10 | Summit Medical Group PA | Florham Park | New Jersey | United States | 07932 |
| 11 | New York Cancer and Blood Specialists | Bay Shore | New York | United States | 11706 |
| 12 | Stony Brook University Hospital | Stony Brook | New York | United States | 11794 |
| 13 | University of Cincinnati - Vontz Center for Molecular Studies | Cincinnati | Ohio | United States | 45267 |
| 14 | Tranquil Clinical Research | Webster | Texas | United States | 78041 |
| 15 | University of Wisconsin Hospitals and Clinics | Madison | Wisconsin | United States | 53792 |
| 16 | Concord Repatriation General Hospital | Concord | New South Wales | Australia | 2139 |
| 17 | The Alfred Hospital | Melbourne | Victoria | Australia | 3004 |
| 18 | William Osler Health Center | Brampton | Ontario | Canada | L6R 3J7 |
| 19 | Centre Hospitalier Universitaire De Sherbrooke (CHUS) - Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hopital Fleurimont | Sherbrooke | Quebec | Canada | J1H 5N4 |
| 20 | Sun Yat-Sen University Cancer Center | Guangzhou | Guangdong | China | 510060 |
| 21 | Wuhan Union Hospital | Wuhan | Hubei | China | 430022 |
| 22 | Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College | Tianjin | Tianjin | China | 300020 |
| 23 | Zhejiang University School of Medicine - The First Affiliated Hospital (Zhejiang Provincial First Hospital) | Hangzhou | Zhejiang | China | 310003 |
| 24 | Fakultni nemocnice Olomouc | Olomouc | Czech | Czechia | 77900 |
| 25 | Vseobecna Fakultni Nemocnice v Praze | Prague | Praha | Czechia | 12802 |
| 26 | FNsP Ostrava | Ostrava | Czechia | 708 52 | |
| 27 | CHRU Lille | Lille | Hauts-de-France | France | 59037 |
| 28 | Institut Paoli-Calmettes | Marseille | Provence-Alpes-Cote d'Azur | France | 13273 |
| 29 | Klinikum Nuernberg Nord | Nuremberg | Bavaria | Germany | 90419 |
| 30 | Universitaetsklinikum Koeln | Cologne | North Rhine-Westphalia | Germany | 50931 |
| 31 | Debreceni Egyetem - Orvos es Egeszsegtudomanyi Centrum (DEOEC) (University of Debrecen Medical and Health Science Center) | Debrecen | Norhtern Great Plain | Hungary | 4032 |
| 32 | Semmelweis University | Budapest | Pannonia | Hungary | 1088 |
| 33 | Del-Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet | Budapest | Pannonia | Hungary | 1097 |
| 34 | Chonnam National University Hwasun Hospital | Hwasun | Jeollanam-do | Korea, Republic of | 58128 |
| 35 | Samsung Medical Center | Seoul | Korea, Republic of | 06351 | |
| 36 | The Catholic University of Korea, Seoul St. Marys Hospital | Seoul | Korea, Republic of | 06591 | |
| 37 | Hospital Espanol Auxilio Mutuo de Puerto Rico, Inc. | San Juan | Puerto Rico | 00918 | |
| 38 | Hospital Universitario Vall d'Hebron | Barcelona | Spain | 08035 | |
| 39 | Fundacion Instituto de Estudios Ciencias de la Salud de Castilla y Leon-Investigacion Biomedica de Salamanca (IBSAL) | Salamanca | Spain | 37007 | |
| 40 | St James's University Hospital - Leeds Teaching Hospitals NHS Trust | Leeds | West Yorkshire | United Kingdom | LS9 7TF |
| 41 | University Hospitals of Derby and Burton NHS Foundation Trust | Derby | United Kingdom | DE22 3NE |
Sponsors and Collaborators
- Takeda
Investigators
- Study Director: Study Director, Takeda
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TAK-573-2001
- 2022-002169-14